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Abstract 
 
Amyotrophic lateral Sclerosis (ALS) is a fatal neurodegenerative disease which 
affects the motor neurons. TDP-43 was identified as the pathogenic protein in ALS. 
The cause of the sporadic ALS is unknown but, there are some links with 
occupations involving heavy labour, exposure to heavy metals, or a history of 
traumatic injury. TDP-43 has been expressed in yeast to act as a disease model for 
ALS. This model exhibits some of the pathological features associated with ALS in 
humans, like cytoplasmic aggregation of the protein and cytotoxicity. In this work, 
yeast model of ALS was studied using fluorescence microscopy and spot assay to 
check for toxic effect of TDP43-YFP expression on the growth of cells. When basal 
level of protein expression is maintained, diffused fluorescence is observed which 
implies the protein is in monomeric state. When the protein is overexpressed, the 
TDP43-YFP fusion proteins tend to aggregate and form fluorescent foci. The 
TDP43-YFP when expressed in yeast forms toxic aggregates which hinders the 
growth of cells. Effect of zinc was also checked on the aggregation of TDP43-YFP. 
The data shows that zinc promotes the aggregation of TDP43-YFP in yeast.  
Alzheimer’s disease (AD) is a neurodegenerative disease and it is the most common 
cause of dementia. When Amyloid Precursor Protein (APP) is cleaved into Aβ 
peptide, the peptide tends to aggregate and form amyloid deposits. The hallmark of 
AD is the presence of extracellular amyloid plaques and intracellular neurofibrillary 
tangles in the brain. These amyloid plaques contain the aggregated Aβ peptide. 
Aβ42 fused to the functional domain of the Sup35, when expressed in yeast acts as a 
disease model for AD. This model has been used for the screening of potential anti-
oligomer drug. Prions can propagate as different strains due to different aggregated 
conformation of the same protein. It has been observed that Arctic and Swedish 
mutations in Aβlead to two prion-like different strains of Aβ. It is being proposed 
here that different variants of Aβ prion, even from wild-type Aβ sequence, can be 
obtained in yeast as well, which can act as a disease model for AD. Furthermore, 
preliminary data show that expression of Aβ42 in yeast causes mitochondrial loss. 
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Chapter 1 
1. Introduction 
 
1.1. Amyloids and Prions 
 
Proper folding of a protein is essential for proper functioning of the protein. When 
the protein is present in a non-native structure the protein is said to be misfolded, the 
residues exposed on the surface might interact with the cellular components causing 
cellular toxicity. Misfolding also causes reduction in the number of native protein 
available to perform its normal function. Protein misfolding is mostly prevented by 
molecular chaperones and degradation process; but, sometimes the protein escapes 
this process and tends to misfold [1]. 
 
 
 
 
 
Misfolding of a protein in general, causes formation of highly organized and thread-
like aggregates called amyloid fibrils. Amyloids have cross-β structure where the 
peptide molecules form β-strands perpendicular to the axis of the fibril [3]. These 
fibrils bind specifically to Thioflavin T (ThT) dye causing increase in the fluorescence 
[2] and Congo red (CR) dye causing green birefringence when viewed under cross-
polarized light [4].  
When these amyloid fibrils are infectious in nature, they are called prions. The word 
prion is derived from protein and infectious. Prions are self seeding, have high 
stability and are resistant to protease [1]. 
Figure 1: Fluorescence spectra of ThT in the absence (solid line) of peptide, and 
in the presence of preaggregated  (1-28) (short dashed line), or  (1-40) peptide 
(long dashed line) A) Excitation spectra B) Emission spectra [2] 
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Prions can propagate as different strains due to different conformation of the protein 
within the protein aggregates. These strains have different pathogenic properties. [5-7] 
 
 
 
 
 
 
 
 
Misfolding of a protein is the main cause of major neurodegenerative diseases like 
Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and the Frontal 
Temporal Dementias [10].  
 
 
 
Disease Amyloid Protein/Peptide 
Alzheimer’s Disease Aβ(40‐42) 
Transmissible Spongiform Encephalopathies Prion Protein (PrP) 
Parkinson’s Disease α-Synuclein 
Amyotrophic Lateral Sclerosis TDP-43 
Huntington’s Disease 
Huntingtin with PolyQ 
Expansion 
 
 
Figure 2: Structural features of Amyloid 
a) Cross-beta structure present in amyloids [8] 
b) Transmission electron microscopy (x100,000) image of amyloid fibrils 
with a diameter of 7.5 to 10 nm [9] 
c) Apple-green birefringence of amyloid fibrils upon binding of Congo red 
under polarized light microscopy. [9] 
a b c 
Table 1:  List of examples of neurodegenerative protein misfolding diseases 
[1, 10, 11] 
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1.2. Yeast: Model for Prion and Amyloid diseases. 
 
The yeast Saccharomyces cerevisiae is an ideal in vivo model to study human disease 
mechanisms [12] due to conserved basic cellular mechanisms, rapid growth on defined 
media and easy mutant isolation [13].Yeast provides a model system for studying 
mechanisms of protein misfolding and aggregation, which is also applicable to human 
diseases [14]. 
Yeast has been used as a model system to study the disease mechanism of various 
neurodegenerative diseases like Alzheimer’s [15], Parkinson’s [16], and Huntington’s 
[17] by expression of the pathological protein. TDP-43 has been expressed in yeast to 
act as a disease model of ALS [18].  
Sup35 protein is involved in the recognition of stop codons in yeast. Sup35  
N-terminal domain [1-123] is unstructured and is responsible for prion formation, the 
highly charged, middle (M) domain [124-254] promotes the non-prion state. The C-
terminal folded domain [255-685] is responsible for its translation termination activity 
[19]. 
 
 
 
When the Sup35 is converted from its soluble non-prion state [psi–] to its aggregated 
prion state [PSI+], termination activity of the protein is reduced, causing the read-
through of stop codons [21]. 
[psi-] cells in ade1–14 background having a premature stop codon, will form red 
colonies on rich growth medium (YPD) due to functional C-terminal region of 
Sup35MC which would perform the translation termination and due to the 
accumulation of a metabolic intermediate of the adenine biosynthesis pathway. 
If the protein is insoluble then it will give white colonies indicative of prion formation 
leading to loss of function of C-terminal of Sup35MC and formation of full length 
Ade1 protein (functional) [22,23].  
Figure.3: Domain architecture of Yeast Sup35 Protein [20]. 
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A previous study done by Sondheimer and Lindquist, shows that the Prion domains are 
modular and transferable. Fusion will not affect the function of Sup35MC [24]. 
 
 
 
 
 
Prion Domain of Pathogenic protein can be fused with Sup35MC and the fusion protein 
can be expressed in yeast to study the mechanism of the disease. The Sup 35 can act as 
a reporter to study the aggregation of the protein. 
Figure 4: The [PSI+] yeast prion. [21] 
Sup35 is soluble in [psi-] state. In ade1–14 background, cells will form red colonies 
on YPD due to functional C-terminal region of Sup35MC which would perform the 
translation termination. When Sup35 is converted to its aggregated prion state 
[PSI+], termination activity is reduced, causing the read-through of stop codons. 
Figure 5: The [RPS+] and [rps-] prion in yeast. Prion domain of Rnq1 when fused 
with Sup35 mimics [PSI+] prion. When the fusion protein is soluble the cells 
appear red on YPD and when the fusion protein is aggregated it forms white 
colonies on YPD. [24]. 
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1.3. Prion strains 
 
Prion variants are called prion strains. Prion variants are present in mammalian as well 
as yeast prions.  Scrapie is a prion disease in sheep, which has two variants: drowsy and 
scratchy [25]. 
 
 
 
 
The variants of yeast prion [PSI+] depend on the level of soluble Sup35 present in the 
yeast cell. The [PSI+] prion exhibits three strains: strong [PSI+] (low level of soluble 
Sup35), weak [PSI+] and [psi–], which appear white, pink and red respectively on 
YPD.  
 
 
 
 
The strong  [PSI+] can grown well on –Ade media, weak [PSI+] grows poorly on –Ade 
and [psi–] cannot grow on –Ade media [26]. They also exhibit faithful propagation of 
the prion variant. Strong [PSI+] being dominant over weak [PSI+] and [psi–] [27].  
Figure 6: Prions can exhibit self propagating variants/strains 
Figure 7: The [PSI+] yeast prion exhibits three variants [26]: Strong 
[PSI+] (White), Weak [PSI+] (Pink) and [psi–] (red). 
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1.4. Amyotrophic  Lateral Sclerosis 
 
Amyotrophic lateral Sclerosis (ALS) is a fatal neurodegenerative disease which 
affects the motor neurons. Upper motor neurons (brain) send the signals to the lower 
motor neurons (spinal cord) which then sends the message to the voluntary muscles. 
ALS causes the degeneration of both upper and lower motor neurons, which causes 
muscular atrophy and muscle twitching. ALS is characterized by progressive 
weakness and death within few years [11]. The major symptoms include difficulty in 
speaking, chewing and swallowing; stumbling while walking and eventually patients lose 
the ability to breathe.  
Prevalence of the disease is 5 individuals per 100,000 and the risk increases after the 
age of 60. Most of the ALS cases are sporadic and only 10% are associated with 
familial mutations [11]. The cause of the sporadic ALS is largely unknown but, there 
are some links with occupations involving heavy labour, exposure to environmental 
toxicants, or a history of traumatic injury [28]. There is no known cure for ALS yet; 
but, the disease progression can be slowed down by an anti-glutamate drug called 
Rilutek which blocks the release of glutamate from the nerve cells. Rilutek prolongs 
median survival by two to three months in ALS patients [29]. 
TDP-43 was identified as the pathogenic protein in ALS, using specific monoclonal 
antibodies [30]. Trans Active Response (TAR) DNA-binding protein 43 (TDP-43) is a 
ubiquitously expressed 414 amino-acid nuclear protein, encoded by TARDBP gene on 
chromosome 1 [31]. Under certain conditions, the protein mislocalises to the 
cytoplasm and forms toxic inclusions; this depletes the nuclear pool of soluble TDP-
43. The pathological TDP-43 is hyperphosphorylated, ubiquitinated and cleaved to 
generate C-terminal fragments of the protein [32].  
Mutations in the TARDBP gene are mostly located in the C-terminal glycine rich 
region [33]. TDP-43 aggregates are non-amyloid like and mutation of the protein in 
the C-terminal region increases its aggregation and cytotoxicity [34]. These 
aggregates are heat and proteinase resistant; transmissible in nature and are able to 
seed the aggregation of the soluble protein. Hence, these aggregates have prion like 
properties [31]. 
TDP-43 was originally identified as a repressor of HIV-1 which binds to the TAR 
DNA element of HIV [31]. Functions of TDP-43 include transcriptional repression 
[35], translational repression [34] and splicing of the CFTR pre-mRNA [36]. 
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TDP-43 is a homodimer with four RNA recognition motifs (RRMs) and a glycine 
rich C-terminal. RRMs have two highly conserved hexameric and octameric 
segments called as ribonucleoprotein 2 (RNP2) and ribonucleoprotein 1 (RNP1) 
respectively. The conserved RNP segments in TDP-43 are involved in binding to 
TAR DNA sequences and RNA sequences with UG-repeats and the C-terminal is 
involved in the splicing [32].  
TDP-43 fused with green fluorescent protein (GFP) has been expressed in yeast to 
act as a disease model for ALS. This model exhibits some of the pathological 
features associated with ALS in humans, like nuclear localisation and cytoplasmic 
aggregation of the protein. And it has been proposed that the toxicity is caused by the 
loss of function of TDP43 protein due to aggregation rather than due to accumulation 
of the protein. [36] 
  
 
 
 
 
 
When basal level of protein expression is maintained, diffused fluorescence is 
observed under fluorescence microscope which implies the protein is in monomeric 
state. When the protein is overexpressed, the TDP43-GFP fusion proteins tend to 
aggregate and form fluorescent foci.   
Figure 8: Domain architecture of TDP-43. [32] 
a b 
Figure 9: Aggregates of TDP-43 
a) Yeast cells showing TDP43-GFP aggregation. [36] 
b) HeLa cells showing cytoplamic aggregation of TDP-43 (green) and the 
nucleus is shown in blue. [37] 
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1.5. Alzheimer’s Disease 
 
Alzheimer’s disease (AD) is a neurodegenerative disease and it is the most common 
cause of dementia. AD is characterized by memory impairment (delayed recall), 
amnestic mild cognitive impairment and Alzheimer’s dementia. Dementia causes 
decline in cognition, function and behaviour. [38] In 2005, 24.2 million people were 
affected by dementia worldwide and 70% of these patients had AD. In of 60 year-
olds population of North America and Western Europe, the prevalence and incidence 
of dementia is the highest. [39]. AD is classified as early onset (onset before 65) and 
late onset (after 65 years) based on the age of onset. Late onset AD affects more than 
95% of the affected individuals. [38] The hallmark of AD is the presence of 
extracellular amyloid plaques and intracellular neurofibrillary tangles in the brain. 
[40]. These amyloid plaques contain the aggregated Aβ peptide [41]. 
 
 
The Amyloid Precursor Protein is a transmembrane protein. Function of this protein 
is not clear but, when it is cleaved into Aβ peptide, the peptide tends to aggregate and 
form amyloid deposits. [43] 
 
 
 
 
Figure 10: Hallmarks of AD: Amyloid plaque and neurofibrillary tangles [42] 
Figure 11: Amyloid Precursor Protein (APP) showing the N-Terminal signal 
peptide, a serine protease inhibitor domain of the Kunitz type (KPI) and amyloid β-
peptide (Aβ) including the transmembrane domain (TM) [43] 
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The Amyloid Precursor Protein (APP) is cleaved by the enzyme β-secretase (BACE). 
Then the γ-secretase enzymes act on the APP to generate Aβ peptide of different 
lengths. The γ cleavage site is variable which decides the length of the peptide and 
determines the ability of the peptide to aggregate. For eg. Aβ-42 is more prone to 
aggregation than Aβ-38. [43] 
   
 
 
 
 
Aβ42 fused to the functional domain of the Sup35, when expressed in yeast produces 
Aβ42-Sup35MC fusion proteins, which in the [PSI+] ade1–14 strain, will give rise to 
rise to red colonies on rich growth medium (YPD) due to functional C-terminal 
region of Sup35MC and will not survive on SD-Ade media as the Ade protein 
produced is truncated. If the protein is insoluble then it will give white colonies 
indicative of prion formation leading to loss of function of C-terminal of Sup35MC 
and formation of full length Ade protein and will survive on SD-Ade. Aβ42-
Sup35MC fusion proteins when expressed in yeast were able to form sodium dodecyl 
sulfate (SDS)-stable low-n oligomers. Yeast growth in SD-Ade was used to assay for 
the formation of oligomers, and the compound which is able to restore the activity of 
the functional domain of Sup35 can act as a potential anti-oligomer drug. [44]. 
Prions can propagate as different strains due to different conformation of the protein 
aggregates and it has been observed that at least two different strains of Aβ prions i.e. 
Arctic and Swedish strains exist leading to different manifestation of the disease [45]. 
It is being proposed that different strains of Aβ prions can be obtained in the yeast 
model as well, which can act as a better disease model for AD.  
a b 
Figure 12: Generation of Aβ peptide [43] 
a) The amyloid precursor protein (APP) is first cleaved by β-secretase (BACE) 
b) Sites where γ-secretase enzymes can act, to release the Aβ peptide. 
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Chapter 2 
2. Materials and Methods 
 
2.1. Materials 
 
All the culture media components, Zinc chloride, Copper chloride and DMSO, were 
purchased from HiMedia. Yeast strain INVSc1 was purchased from Invitrogen. 
Qiagen mini-prep kit was purchased from Qiagen. Ammonium Sulphate was 
purchased from SRL. Ampicillin Sodium salt, galactose, glycine, histidine,  
L- Leucine, L- Tryptophan, Lithium acetate, uracil and raffinose were purchased 
from Sigma. Yeast strains and plasmids were kind gifts from Dr. Susan Liebman. 
 
2.2. Methods used for studying TDP-43 
 
2.2.1.  Preparation of Media 
Bacterial culture media 
Luria Bertani (LB) + Ampicilin media was used for reviving and maintaining the 
bacterial transformants containing pRS416Gal TDP43 WT YFP and pRS416 
plasmids. These plasmids have ampicilin as antibiotic selection marker. LB media 
contains Tryptone (1%), yeast extract (0.5%) and sodium chloride (1%). The pH 
was adjusted to 7 using sodium hydroxide and for the preparation of solid media 
1.5% agar was used. Media was autoclaved for 20 minutes at 121 °C. The media 
was cooled to 60°C and 1 ml from 1mg/ml ampicilin stock, was added to the 
media. 
Yeast culture media 
Standard yeast media YPD [46] was used for reviving yeast strains from -80°C. 
YPD is a non selective rich media which contains 1% Yeast extract, 2% Peptone 
and 2% Dextrose. For preparation of solid media 2% agar was added. The media 
was autoclaved for 20 minutes at 121 °C.   
For maintaining the plasmid and for the selection of plasmid containing yeast 
transformants, synthetic “dropout” media was used which contains all the 
nutrients except for uracil. The synthetic defined media used were SD-Ura (2% 
Dextrose) and SRaf-Ura (1% Raffinose) containing Yeast Nitrogen Base (YNB), 
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Ammonium Sulfate (AS) and all the amino acids except uracil. For preparation of 
solid media 2% agar was added. Media was autoclaved for 18 minutes at 115 C. 
Yeast strains were grown at 30°C and stored at 4°C.  
While checking the effect of the metal ions and the small molecule, these 
compounds were added along with the SRaf (1%) +0.1%Gal-Ura media. 
Galactose solution, salt solution and 3-Aminophenol solutions were filter 
sterilized before addition to the media. 
 
2.2.2. Plasmid Isolation and Yeast Transformation 
Plasmid pRS416Gal TDP43 WT YFP is a low copy number Yeast Centromeric 
Plasmid (YCP) under GAL promoter. This plasmid when transformed in INVSc1 
yeast expresses TDP-43-YFP fusion proteins under GAL promoter. The 
expression of the protein can be induced by galactose and the level of expression 
can be controlled by changing the concentration of galactose. 
 
 
 
Figure 13: Plasmid map of pRS416Gal TDP43 WT YFP 
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Plasmid Isolation: Mini prep 
Plasmid pRS416Gal TDP43 WT YFP and pRS416 (control plasmid) were 
isolated using Qiagen mini-prep kit. Buffer P1 (50 mM Tris-HCl pH 8.0, 10 mM 
EDTA, 100 μg/ml RNaseA), Buffer P2 (200 mM NaOH, 1% SDS), Buffer N3 
(4.2M Gu-HCl, 0.9M potassium acetate, pH 4.8), Buffer PB (5M Gu-HCl, 30% 
isopropanol and Buffer PE (10 mM Tris-HCl, pH 7.5, 80% ethanol) 
 
1. The bacterial transformants were grown overnight in LB+Amp broth in 
rotary shaker at 200 rpm at 37°C. 
2. Cells were pelleted by centrifuging at 6000 rpm for 5 mins at 4°C. 
3. The supernatant was discarded and the cells were resuspended in 250l of 
P1 (containing RNase A) buffer. 
4. 250 l P2 buffer was added and mixed thoroughly till the solution turned 
clear blue. 
5. 350 l of N3 buffer and was mixed thoroughly by inverting the tube until 
the solution becomes clear and colorless. 
6. Centrifuged for 10 min at 13000 rpm. 
Figure 14: Plasmid map of pRS416 
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7. Supernatant from previous step (6) was applied to the QIA prep spin 
column by pipetting and centrifuged at 13000 rpm for 2 mins, and the 
flow through was discarded 
8. 500 l PB buffer was added and allowed to stand for 1 min then 
centrifuged at 10000 rpm for 2 mins and the flow through was discarded. 
9. 700 l PE buffer was added and was centrifuged at 10000 rpm for 2 mins 
and the flow through was discarded. 
10. Residual ethanol in the column was allowed to dry and the column was 
centrifuged for 2 mins at 10000 rpm. 
11. The QIA prep column was placed in a clean eppendorf and 50l of 
autoclaved water was added to the center of the column. 
12. This was allowed to stand for 5mins and centrifuged at 14000 rpm for 2 
mins and the concentration was found using nanodrop. And the plasmid 
was stored at -20°C 
 
Yeast Transformation: PEG/Lithium acetate-DMSO method 
The yeast strain INVSc1: MATa his3D1 leu2 trp1-289 ura3-52 MAT 
his3D1 leu2 trp1-289 ura3-52 was revived on Yeast extract Peptone 
Dextrose (YPD) plate. Both the TDP43-YFP and Control plasmids were 
transformed into INVSc1 using PEG/Lithium acetate-DMSO method. The 
transformants were selected on synthetic complete dextrose media lacking 
uracil (SD-Ura plate) as the plasmids contain URA3 as selectable marker. 
1. A single colony of Inv.Sc.1 was inoculated in 5 ml YPD broth and 
incubated overnight in rotary shaker at 200 rpm at 30°C. 
2. 2 ml of overnight pre-inoculum was added to 60 ml YPD broth and was 
incubated till the O.D reaches 1.0 (~5 hours) in rotary shaker at 200 rpm at 
30°C. 
3. The cells were pelleted by centrifuging at 10000 rpm for 5 mins and 
washed with 1 ml water and 1 ml 1X TE-LiAc at 10000 rpm for 2 mins. 
4. The cells were resuspended in 250 l 1X TE-LiAc and 5l of plasmid 
(TDP43-YFP and Control plasmid) and 5 l carrier DNA was added. The 
carrier DNA was boiled for 10 min at 95°C and was placed on ice 
immediately before adding. 
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5. 300 l of sterile 1X PEG-LiAc was added and incubated at 30°C for 60 
mins with occasional shaking. 
6. 40 l DMSO was added and mixed thoroughly then heat shock at 42°C 
for 15 mins. 
7. The cells were pelleted at 10000 rpm for 5 mins and resuspended in 100 
l autoclaved water.  
8. The cells were spread on SD-Ura plate and allowed to grow for 3-5 days. 
1.  
2.2.3. Spot Assay to study the toxicity of TDP-43 expression in yeast cells. 
1. The INVSc1+TDP43-YFP  transformants from the SD-Ura plate were 
picked from the plate and inoculated in 10 ml of SD-Ura media 
2. The cells were grown to an optical density of 0.6 OD600, at 30°C in a rotary 
shaker at 200 rpm; till they reach log phase. 
3. One to five fold serial dilutions were performed using 100 l of the 
culture. 
4. 5 l of the culture was spotted and allowed to dry. 
5. Triplicates of each dilution were spotted on each plate: YPD, SD+12, SD-
Ura, SRaf-Ura, SRaf-Ura + 2% Gal and SRaf-Ura + 0.1% Gal. 
6. Incubated at 30°C, for 48 hours. 
 
2.2.4. Spot Assay to study the effect of 3-Aminophenol on toxicity of TDP-43 
expression in yeast cells. 
1. The INVSc1+TDP43-YFP  transformants from the SD-Ura plate were 
picked from the plate and inoculated in 10 ml of SD-Ura media 
2. The cells were grown to an optical density of 0.6 OD600, at 30°C in a rotary 
shaker at 200 rpm; till they reach log phase. 
3. One to five fold serial dilutions were performed using 100 l of the 
culture. 
4. 5 l of the culture was spotted and allowed to dry. 
5. Triplicates of each dilution were spotted on each plate: SD+12, SD-Ura, 
SRaf-Ura + 2% Gal, SRaf-Ura + 0.1% Gal, SRaf-Ura + 0.2% Gal and 
SRaf-Ura + 0.2% Gal + 3mM 3-Aminophenol. 
6. Incubated at 30°C, for 48 hours. 
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2.2.5. Selection of Carbon source to study the effect of zinc/copper [47] 
1. Inv Sc1 + TDP43-YFP cells were grown in a rotary shaker at 200 rpm and 
30°C, for 24 hours in 5 ml of SD-Ura. 
2. 100 l of this culture was inoculated in 5ml of: 
1) SRaf–Ura  
2) SRaf–Ura + 10mM Zinc chloride 
3) SRaf–Ura + 5mM Copper sulphate 
4) SD–Ura  
5) SD–Ura + 10mM Zinc chloride 
6) SD–Ura + 5mM Copper sulphate 
3. The culture was allowed to grow overnight in a rotary shaker at 200 rpm 
and 30°C; 2 ml of the culture was centrifuged and washed with 1 ml of 
autoclaved water to remove traces of media 
4. The pellet was resuspended in 200 l of water.  
5. 100 l of this culture was serially diluted in 900 l of water up to 10000 
dilutions. 
6. 5 l was spotted on SD-Ura plate and YPD. 
7. The growth was checked after 48 hours. 
 
2.2.6. Effect of 1% Galactose and 10mM zinc chloride / 5mM copper sulphate 
1. Inv Sc1+TDP43-YFP cells were grown in 10 ml of SRaf-Ura for 24 hours 
in a rotary shaker at 200 rpm and 30°C. 
2. The absorbance was measured at 600 nm after 24 hours taking SRaf-Ura 
media as blank. 
3. 200 l of this culture was inoculated in 5ml of: 
1. SRaf – Ura 
2. SRaf + 1% Galactose. 
3. SRaf + 1% Galactose + 10mM Zinc chloride 
4. SRaf + 1% Galactose + 5mM Copper sulphate 
4. The experiment was performed in triplicates. 
5. The culture was allowed to grow overnight in a rotary shaker at 200 rpm 
and 30°C; and the absorbance was measured at 600nm. 
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6. 2ml of the culture was centrifuged and washed with 1ml of water to 
remove traces of media 
7. The pellet was resuspended in 200 l of water. 
8. 100 l of this culture was serially diluted in 900 l of water up to 1000 
dilutions. 
9. 5 l was spotted on SD-Ura plate. 
10. Growth was checked after 3 days. 
 
2.2.7. Optimization of zinc concentration 
1. Inv Sc1 + control plasmid was grown overnight in 5 ml of SD-Ura in a 
rotary shaker at 200 rpm and 30°C. 
2. 100 l of this culture was inoculated in 5 ml of:  
1) SD–Ura  
2) SD+ 0.1mM Zinc chloride-Ura  
3) SD+ 0.5mM Zinc chloride-Ura  
4) SD+ 1mM Zinc chloride-Ura  
5) SD+ 2mM Zinc chloride-Ura  
6) SD+ 4mM Zinc chloride-Ura  
7) SD+ 6mM Zinc chloride-Ura  
8) SD+ 8mM Zinc chloride-Ura  
3. The culture was allowed to grow overnight in a rotary shaker at 200 rpm 
and 30°C. 5 ml of the culture was centrifuged and washed with 1 ml 
autoclaved water to remove traces of media. 
4. The pellet was resuspended in 200 l autoclaved water. 100 l of this 
culture was serially diluted in 900 l of autoclaved water up to 1000 
dilutions. 
5. 5 l was spotted on SD-Ura and SD+12 plates. The growth was checked 
after 48 hours at 30°C. 
 
2.2.8. Optimization of copper concentration 
1. Inv Sc1 + control plasmid cells were grown overnight in 5 ml of SRaf-Ura 
in a rotary shaker at 200 rpm and 30°C. 
2. 100 l of this culture was inoculated in 5 ml of:  
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1. SRaf–Ura  
2. SRaf-Ura + 10 M Copper sulphate  
3. SRaf-Ura + 50 M Copper sulphate  
4. SRaf-Ura + 100 M Copper sulphate  
3. The culture was allowed to grow overnight in a rotary shaker at 200 rpm 
and 30°C. 3 ml of the culture was centrifuged and washed with 1 ml 
autoclaved water to remove traces of media. 
4. The pellet was resuspended in 200 l autoclaved water and the cells were 
normalized. 100 l of this culture was serially diluted in 900 l of 
autoclaved water up to 1000 dilutions. 
5. 5 l was spotted as duplicates on SD-Ura. The growth was checked after 
48 hours at 30°C. 
 
2.2.9. Optimisation of Galactose concentration 
1. Inv Sc1 + control plasmid, Inv Sc1 + TDP43-YFP, Yeast A (TDP43-YFP) 
were grown overnight in 5 ml of SRaf-Ura at 30°C. 
2. The absorbance of the culture was measured and the OD was normalized 
to 0.36 OD. 
3. 100 l of this culture serially diluted in 900 l autoclaved water up to 1000 
dilutions. 
4. 5 l was spotted  as duplicates on plates: 
1) SRaf(1%)-Ura + 0.0001% Gal 
2) SRaf(1%)-Ura + 0.001% Gal 
3) SRaf(1%)-Ura + 0.01% Gal 
4) SRaf(1%)-Ura + 0.1% Gal 
5) SRaf(1%)-Ura + 1% Gal 
6) SRaf(1%)-Ura + 2% Gal 
5. Growth was checked after 48 hours of incubation at 30°C. 
 
2.2.10. Fluorescence Microscopy to check for different levels of expression of 
TDP43-YFP 
1. Cells in the log phase from the different plates [SRaf(1%)-Ura + 0.0001% 
Gal, SRaf(1%)-Ura+0.001% Gal, SRaf(1%)-Ura+0.01% Gal, SRaf (1%)-
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Ura+0.1% Gal, SRaf(1%)-Ura + 1% Gal, SRaf(1%)-Ura + 2% Gal] were 
suspended in 10l of autoclaved water on a micro slide and were covered 
with a cover slip. 
2. The cells were first observed under 40 x magnifications. 
3. Then a drop of immersion oil was placed on the cover slip and the cells 
were observed under oil immersion 63x and 100x magnification. 
 
2.2.11. Effect of 0.1% and 1% Galactose and 3mM Zinc chloride 
1. Inv Sc1 + control plasmid and Inv Sc1 + TDP43-YFP was grown 
overnight in 5ml of SRaf-Ura. 
2. 100 l of culture was inoculated in 5l of:  
1. SRaf–Ura 
2. SRaf+ 0.1% Gal –Ura 
3. SRaf+ 0.1% Gal + 3mM Zinc chloride-Ura  
4. SRaf+ 1% Gal –Ura 
5. SRaf+ 1% Gal + 3mM Zinc chloride-Ura 
3. The culture was allowed to grow overnight and 2 ml of the culture was 
centrifuged and washed with 1 ml of autoclaved water to remove traces 
of media. 
4. The pellet was resuspended in 200 l of water. 100 l of this culture was 
serially diluted in 900 l of water up to 1000 dilutions. 
5. 5 l was spotted on two SD-Ura plates. The growth was checked after 48 
hours. 
  
2.3. Methods used for studying Aβ42-Sup35MC fusion  
The yeast strain 74D-694 (MATa ade1-14 ura3-52 leu2-3,112 trp1-289 his3-200) 
[48] where the genomic SUP35 (sup35Δ::LEU2) [49] and ERG6 of the ergosterol 
biosynthetic pathway was deleted [50] carrying the plasmid p1364 (pRS313, CEN, 
Ura3, CUP1:: A-MRF) [51] was used as a disease model of Alzheimer’s disease. 
 
2.3.1. Preparation of Media 
YPD was used [43] for reviving yeast strains from -80°C. YPD is a non 
selective rich media which contains 1% Yeast extract, 2% Peptone and 2% 
Dextrose. For preparation of solid media 2% agar was added. YPG contains 
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2% Glycerol instead of 2% dextrose and it forbids the growth of respiratory 
defective petite cells which cannot survive on non fermentable carbon sources 
and allows the growth of healthy cells [52]. The media was autoclaved for 20 
minutes at 121 °C. YPD was cooled to 60°C and 50 l from 10mM Copper 
sulfate stock solution, was added to 10 ml media to make YPD+50 M Copper 
sulphate (CuSO4) broth. Aβ42-Sup35MC is under CUP1 promoter which can 
be induced with 50 M CuSO4. Yeast strains were grown at 30°C and stored at 
4°C. 
 
2.3.2. Toxicity of Aβ42-Sup35MC expression in yeast 
1. The yeast strain was revived from -80°C on a YPD plate and was 
subcultured on YPD plates. 
2. The cells were streaked on YPG plates and were incubated for 5 days at 
30°C for the selection of healthy cells. 
3. Cells from the YPG plate were inoculated in 10 ml YPD broth and in 10 
ml YPD+50M CuSO4 broth. And the cells were grown till 0.6 OD600 in a 
rotary shaker at 200 rpm, at 30°C.  
4. One to five fold serial dilutions were performed using 100 l of the 
culture.  
5. 5l of the culture was spotted in triplicates on YPD and YPG plates and 
was incubated at 30°C, for 2 days (YPD) and 5 days (YPG). 
 
2.3.3. Search for Aβ42-Sup35MC amyloid variants  
1. Cells from YPD were streaked on YPG plates and were incubated for 5 
days at 30°C for the selection of healthy cells. 
2. Cells from the YPG plate were inoculated in 10 ml YPD broth and in 10 
ml YPD+50M CuSO4 broth. And the cells were grown till 0.6 OD600 in a 
rotary shaker at 200 rpm, at 30°C.  
3. One to five fold serial dilutions were performed using 100 l of the 
culture.  
4. 100 l of the culture was spread on YPD plates in triplicates and was 
incubated at 30°C, for 2 days (YPD) and 5 days (YPG). 
Chapter 3 
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3. Results and discussion 
 
3.1. Toxicity of TDP-43 expression in yeast cells. 
Spot assay was performed to study the toxicity caused by aggregation of TDP-43 in 
yeast cells. 
 
 
 
The YPD serves as a rich media which supports the growth of transformed and as 
well as non-transformed yeast cells. Growth on synthetic complete media (SD+12) is 
restricted compared to rich media. Synthetic media lacking uracil (SD-Ura) selects 
for transformed colonies having the plasmid with a URA3 selection marker. To 
overcome the problem of glucose repression in the yeast cells, raffinose was used as 
the carbon source in SRaf-Ura plate. The protein was overexpressed by inducing the 
promoter with 2% Galactose. When the protein was expressed by inducing the 
promoter with 0.1% galactose, the toxicity was reduced compared to the 2% 
galactose sample. These results show that expression of TDP-43 in yeast cells, results 
in the inhibition of growth. 
  
Figure 15: Spot Assay to study the toxicity of TDP-43 expression in yeast cells. 
21 
 
3.2. Spot Assay to study the effect of 3-Aminophenol on toxicity of TDP-43 
expression in yeast cells. 
The fusion protein when overexpressed by inducing with 2% Galactose causes high 
toxicity. And when the protein was expressed by inducing the promoter with 0.1% 
and 0.2% galactose, the toxicity was reduced compared to the 2% galactose sample. 
3-Aminophenol when used with 0.2% Galactose induction causes high toxicity which 
is comparable to 2% Galactose sample. These results show that 3-Aminophenol is 
increasing the toxicity caused by expression of TDP-43 in yeast cells, results in the 
inhibition of growth. 
 
 
  
Figure 16: Spot Assay to study the effect of 3-Aminophenol on toxicity of 
TDP43-YFP expression in yeast cells. 
22 
 
3.3. Selection of Carbon source 
The cell grown in SD-Ura broth face the problem of glucose repression in the yeast 
cells and when raffinose was used as the carbon source, the cell growth is better. 
When the cells are exposed to 10 mM Zinc chloride or 5 mM Copper sulphate [47], 
the cell growth is further hindered in the SD-Ura sample owing to the toxic effects of 
zinc/copper and glucose repression. 
 
 
  Figure 17: Selection of Carbon source 
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3.4. Effect of 1% Galactose and 10mM zinc chloride /5mM copper sulphate 
1% Galactose induction causes high expression of TDP43-YFP fusion protein and 
the concentration of zinc chloride and copper sulphate used was determined from a 
previous work [47]. High expression of TDP43-YFP along with Zinc chloride is 
causing toxicity compared to 1% galactose sample. Copper sulphate in mill molar 
concentration is causing very high toxicity compared to 1% Galactose sample. 
 
 
 Figure 18: Effect of zinc/copper along with high expression TDP43-YFP.  
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3.5. Optimization of Zinc Concentration 
 
 
 
 
To find the optimum concentration of zinc, different concentrations of were checked 
The optimum concentration of zinc was found to be between 2 mM and 4 mM i.e.  
3 mM. If the concentration of Zinc is more than 3 mM, zinc itself is toxic to the cells 
as the growth is hindered and the effect of expression of TDP43-YFP cannot be 
studied. 
 
3.6. Optimization of Galactose concentration 
TDP43-YFP is under Gal promoter and when the promoter is induced with a high 
concentration of galactose the protein is overexpressed and the protein tends to 
misfold. The misfolding leads to aggregation of the protein. If the protein aggregates 
are not amyloid they are degraded by the cell. If the aggregates are amyloid then they 
seed the normal soluble protein as well. This causes the depletion of normal protein 
which is soluble. And this causes growth inhibition in cells.  
The optimal concentration of galactose where a balance of aggregation and toxicity 
was observed was 0.1% Galactose. 
Figure 19: Optimization of Zinc Concentration 
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3.7. Fluorescence microscopy to check for different levels of expression of TDP43-
YFP 
Greyscale images were obtained from the experiments and the image was processed 
by ImageJ software developed at the National Institutes of Health. 
To check the time required for formation of fluorescent foci, the cells were incubated 
for different intervals of time 24 hours, 48 hours and 72 hours. After 24 hours of 
over-expression, the cells tend to lose the plasmid owing to the toxicity caused by 
TDP-43. To check effect of different levels of expression of TDP43-YFP in yeast 
different   concentration of galactose 0.0001% 0.001%, 0.01%, 0.1%, 1% and 2% 
concentrations were tested and the fluorescence was checked. 
2% and 1% sample showed fluorescent dots due to the aggregation of TDP43-YFP. 
0.1% and 0.01% Galactose were found to be the optimum concentration for the 
maintenance of TDP43-YFP foci. 
Figure 20: Optimization of Galactose concentration 
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0.001% and 0.0001% are showing diffused fluorescence which shows basal level of 
protein expression 
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3.8. Effect of 0.1% Galactose and 3mM zinc chloride. 
The concentration of galactose and zinc as determined by previous experiments was 
used. 0.1% galactose was used to maintain the balance between aggregation and 
toxicity caused by the protein. 
 
 
 
Figure 21: Fluorescent and DIC images indicating different level of TDP43-YFP 
expression 
Figure 22: Effect of 0.1% Galactose and 3mM ZnCl2 
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3.9. Effect of 1% Galactose and 3mM zinc chloride. 
The concentration of galactose and zinc as determined by previous experiments was 
used. 1% galactose was used for high level of expression of the protein. Toxicity 
caused by the protein increased in presence of zinc  
 
 
3.10. Concentration optimization of  copper sulphate  
Results obtained from the previous experiments suggest that mill molar 
concentration of copper is toxic to the cells. The micro molar concentrations are 
not toxic to the yeast cells. Hence, concentrations in the range of 0.1 mM to 5 mM 
needs to be checked. 
 
 
Figure 23: Effect of 1% Galactose and 3mM ZnCl2 
Figure 24: Optimization of copper concentration  
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3.11. Toxicity of Aβ42-Sup35MC expression in yeast 
Aβ42-Sup35MC was expressed by inducing the CUP promoter with 50 M 
copper sulphate. Growth of cells expressing Aβ42-Sup35MC (YPD+50 M 
copper sulphate) is lesser than the cells not expressing Aβ42-Sup35MC 
(YPD).  
YPG contains 2% Glycerol instead of 2% dextrose and it forbids the growth of 
respiratory defective petite cells which cannot survive on non fermentable 
carbon sources and allows the growth of healthy cells [52]. 
The cells expressing Aβ42-Sup35MC seem to have mitochondrial dysfunction 
as the cell growth is inhibited on YPG plate as compared to the cells not 
expressing Aβ42-Sup35MC. 
 
  
 
3.12. Search for Aβ42-Sup35MC amyloid variants  
 
Aβ42 fused to the functional domain of the Sup35, when expressed in yeast 
produces Aβ42-Sup35MC fusion proteins, which in the [PSI+] ade1–14 strain, 
will give rise to rise to red colonies on rich growth medium (YPD) due to 
functional C-terminal region of Sup35MC. If the protein is insoluble then it 
will give white colonies indicative of prion formation leading to loss of 
function of C-terminal of Sup35MC. It has been observed that at least two 
different strains of Aβ prions i.e. Arctic and Swedish strains exist [45]. It is 
Figure 25: Growth of cells expressing Aβ42-Sup35MC on YPD and YPG 
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being proposed that different strains of Aβ can be obtained in the yeast model, 
which can act as a better disease model for AD.  
 
 
 
 
Cells on YPD not expressing Aβ42-Sup35MC fusion protein show 7.14% (5/70) 
petite cells. And cells expressing Aβ42-Sup35MC fusion protein show 13.12% 
(29/221) petites.  
 
 
 
 
 
Figure 26: Different coloured strains (White, pink and red) of  
Aβ42-Sup35MC fusion protein in yeast cells. 
 
Figure 27: Showing petite cells are more in Aβ42-Sup35MC expressing cells 
induced with 50 M copper sulphate, than the non expressing cells. Healthy 
colony is indicated by green arrow and petite colony indicated by yellow 
arrow. 
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Chapter 4 
4. Conclusion 
 
In this work, yeast model of ALS was studied using fluorescence microscopy and spot 
assay to check for toxic effect of TDP43-YFP expression on the growth of cells. When 
basal level of protein expression is maintained, diffused fluorescence is observed which 
implies the protein is in monomeric state. When the protein is overexpressed, the TDP43-
YFP fusion proteins tend to aggregate and form fluorescent foci. The TDP43-YFP when 
expressed in yeast forms toxic aggregates which hinders the growth of cells. Effect of 
zinc was also checked on the aggregation of TDP43-YFP. The data shows that zinc 
promotes the aggregation of TDP43-YFP in yeast. 
Aβ42 fused to the functional domain of the Sup35, when expressed in yeast acts as a 
disease model for AD. This model has been used for the screening of potential anti-
oligomer drug. Prions can propagate as different strains due to different conformation of 
the protein aggregates and it has been observed that at least two different strains of Aβ 
prions i.e. Arctic and Swedish strains exist. It is being proposed that different strains of 
Aβ prions can be obtained in yeast model as well, which can act as a better disease model 
for AD. Preliminary data shows that expression of Aβ42 in yeast causes mitochondrial 
dysfunction. 
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